Joshua Lehrer-Graiwer
Geen lopende functies
Vermogen: 4 M $ op 31-03-2024
Profiel
Joshua Lehrer-Graiwer formerly worked at Graphite Bio, Inc., as President, CEO, CFO, CAO & Director in 2023 and Global Blood Therapeutics, Inc., as Chief Medical Officer from 2019 to 2020.
Dr. Lehrer-Graiwer received his undergraduate degree from Harvard University, graduate degree from the University of Cambridge, and doctorate degree from The University of California, San Francisco.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
0.65% | 01-02-2024 | 165 953 ( 0.65% ) | 4 M $ | 31-03-2024 |
Eerdere bekende functies van Joshua Lehrer-Graiwer
| Bedrijven | Functie | Einde |
|---|---|---|
| LENZ THERAPEUTICS, INC. | Chief Executive Officer | 21-08-2023 |
| GLOBAL BLOOD THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 17-04-2020 |
Opleiding van Joshua Lehrer-Graiwer
| Harvard University | Undergraduate Degree |
| University of Cambridge | Graduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Graphite Bio, Inc.
 Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
